About 50% of all patients suffering from HF exhibit a reduced ejection fraction (EF ≤ 40%),
termed HFrEF. The others may be classified into HF with midrange EF (HFmrEF, EF = 40-50%) or
preserved ejection fraction (HFpEF, EF ≥ 50%).
Up to now, there are no large scale studies evaluating patients with HFmrEF and/or HFpEF in
Turkey. Scarce data are available in the middle-east populations in general and Turkish
patients in particular, who have different etiology, ethnic, cultural backgrounds and risk
factors from those patients in the West. The aim of this study was to study Turkish patients
with HFmrEF and HFpEF, and define their clinical characteristics and the signs and symptoms
of heart failure, echocardiographic findings and medications at admission. With this national
study, we will evaluate how recommendations of most recent European guidelines regarding
pharmacological and non-pharmacological treatments are adopted in clinical practice. We will
also evaluate the prevalence of the clinical profiles of patients with HFmrEF and HFpEF,
according to the definitions proposed by the European Society of Cardiology, and to
investigate their appropriateness in characterizing patients with different clinical
presentations and needs.
Assessed outcomes included the causes of decompensation, use of medications, care quality